The concept of innovative drugs continues to rebound, with GZBL and Luoxin Pharmaceutical both hitting the daily limit
The concept of innovative drugs continues the rebound momentum from yesterday, with GZBL and Luoxin Pharmaceutical hitting the daily limit, Sanofi's stock rising over 10%, and Laimei Pharmaceutical, Hainan Haiyao, Guangshengtang, and Yifang Biotechnology also following suit